Get notified of page updates

Update: Genetic causes of hereditary pancreatic cancer: BRCA and beyond

Printer Friendly Page

Contents

At a glance Clinical trials                       
Beyond       Guidelines            
Genes associated with pancreatic cancer Questions to ask your doctor          
What does this mean for me? Resources and references


UPDATE AT A GLANCE

This update is about:

Inherited mutations in pancreatic cancer genes and the importance of identifying patients who have them.

Why is this update important?

Between 10–20 percent of all pancreatic cancer is thought to be due to an inherited mutation.

  • About 3-10 percent of people with pancreatic cancer have a family history of the disease. 
  • Inherited mutations in and are the most common cause of familial pancreatic cancer. Together, about 6 percent of all pancreatic cancer patients have an inherited mutation in or .
  • Almost 14 percent of people with pancreatic cancer have a mutation.
  • Studies looking at patients who do not have a family history of pancreatic cancer have found that 4-11 percent have an inherited mutation in a gene associated with pancreatic cancer.

Beyond

Genetic panel testing, which looks for mutations in many genes at one time rather than just 1 or 2 at a time, has become more widespread in recent years and has led to a better understanding of which genes contribute to hereditary pancreatic cancer. Genes that are generally included in panel testing include , , , CDKN2A, , , , , and .

Of these genes, panel testing has shown that:

  • Mutations in are found in 2-3 percent of pancreatic cancer cases.
  • Mutations in genes (, , , and ) are found in <1 percent of cases.
  • Mutations in other genes (CDKN2A, , and ) are found in fewer than < 1 percent of cases.

One study found that 17 percent of patients with a family history of pancreatic cancer who had panel testing had an inherited mutation, suggesting the importance of family history. Being diagnosed at a younger age was also associated with an increased likelihood of having a mutation.

Genes associated with hereditary pancreatic cancer and risk

The lifetime risk for pancreatic cancer in the general population is 1.6 percent. The general population includes people with and without mutations. People with the following mutations had an increased risk for pancreatic cancer compared to people without a mutation.

Gene     Increase in Pancreatic Cancer Risk Compared to 
Someone Without the Mutation
Other Associated Cancers
           Unclear Breast
    2-4 times Breast, ovarian,
3-8 times Breast, ovarian, , melanoma
CDKN2A 13-22 times    Melanoma
, , ,  
()
Up to 9 times Colorectal, endometrial (uterine), ovarian,
     Unclear Breast
()    132 times    Breast, gastrointestinal, gynecological
Source: Robert Pilarski, MS, LGC, MSW, LSW, ASCO June 2019

Summary:

In addition to mutations in and , numerous other inherited mutations increase the risk of pancreatic and other cancers. The National Comprehensive Cancer Network (NCCN) now recommends that all pancreatic cancer patients be offered genetic testing and counseling to determine whether they have inherited a . Those who test positive for an inherited mutation may be eligible for different treatment options, such as PARP inhibitors or immunotherapies, and they may require screening for additional cancers. They may also need to alert their family members to the increased risks of certain cancers.  Finally, the identification of mutations may make a patient eligible for specific clinical trials that are looking at targeted therapies for carriers of particular mutations.

What does this mean for me?

If you have been diagnosed with pancreatic cancer, you should speak with your health care provider about receiving genetic counseling and testing to determine if you might carry an inherited mutation in a gene that is associated with hereditary pancreatic cancer. The results may be important for your treatment (including enrollment in clinical trials) and for your family.

If you have a family history of pancreatic cancer, you should speak with a health care provider about referral for genetic counseling and testing. 

If you do not have pancreatic cancer but you know that you carry an inherited mutation in a relevant gene (see the table in this article) and you meet the screening guidelines outlined here, you should speak to your health care provider about receiving annual screening for pancreatic cancer.

Conclusions:

Inherited mutations in a number of genes are associated with increase pancreatic cancer risk. It is important that people with pancreatic cancer are offered genetic testing and counseling to determine if they carry a in one of these genes, as the results can impact treatment decisions, screening and risk management for other cancers, and family members’ risk. It is also important that people without pancreatic cancer but with an inherited mutation in a known pancreatic cancer risk gene are aware of screening guidelines and receive screening as appropriate.

Share your thoughts on this XRAYS article by taking our brief survey.

(back to top)

This article is relevant for:

People diagnosed with pancreatic cancer

This article is also relevant for:

People with a genetic mutation linked to cancer risk

Newly diagnosed

Pancreatic cancer survivors

Be part of XRAY:

Expert Guidelines
Expert Guidelines

Genetic Counseling and Testing Guidelines:

The National Comprehensive Cancer Network (NCCN) and The American Society of Clinical Oncologists (ASCO) recommend that all patients who are diagnosed with pancreatic cancer be offered genetic counseling and testing.  

Pancreatic cancer screening Guidelines:

While numerous studies in the past have found no benefit (or an unclear benefit) to screening the general population for pancreatic cancer, recent research indicates that it is beneficial to screen people at higher risk.

International Cancer of the Pancreas Screening Consortium guidelines

  • International Cancer of the Pancreas Screening Consortium (ICPSC) recommends endoscopic and/or for anyone who has:
    • an mutation.
    • a , , MSH1, , PMS2 or CDKN2A mutation and a first-degree relative with pancreatic cancer.
    • a first-degree relative and one other relative with pancreatic cancer.
  • The ICPSC has not reached a consensus on the age(s) when screening should begin.

American College of Gastroenterology guidelines:

  • The American College of Gastroenterology agrees with the ICPSC guidelines and also suggests that people with a mutation in , , , , MSH1, , or and a first- or second-degree relative be offered screening.
  • They recommend endoscopic and starting at age 50 or 10 years before the earliest diagnosis of pancreatic cancer in the family except for people with mutations, who should begin screening at age 35.

Expert Guidelines
Expert Guidelines

National Comprehenvice Cancer Network (NCCN) Guidelines

The NCCN recommends the following screening for people at increased risk for pancreatic cancer: 

  • Discuss the benefits and risks of screening with their doctor. Screening should be performed by a facility that is experienced with screening for pancreatic cancer. The recommended age for considering screening depends on a person’s family history of pancreatic cancer and varies by type of gene mutation.
    • Consider screening with magnetic resonance cholangiopancreatography (MRCP) and/or endoscopic  (EUS)
    • Consider participating in a pancreatic cancer screening study

NCCN recommends that people with inherited mutations in the following genes (with or without a family history of cancer) "consider pancreatic cancer screening" with MRCP or EUS:

  • : (): Consider pancreatic cancer screening by MRCP or EUS every 1-2 years beginning at age 30-35 or 10 years younger than the earliest pancreatic cancer in the family.
  • CDKN2A: Consider pancreatic cancer screening beginning at age 40 or 10 years earlier than the earliest pancreatic cancer diagnosis in the family.

NCCN guidelines recommend that people with an inherited mutation in one of the following genes and a family history of cancer "consider pancreatic cancer screening" with MRCP or EUS beginning at age 50 or 10 years earlier than the earliest pancreatic cancer diagnosis in the family: 

NCCN does not currently recommend pancreatic cancer screening for people with the above mutations who do not have a family history of cancer. 

American Society for Gastrointestinal Endoscopy (ASGE) Guidelines

In February 2022, the ASGE released updated guidelines on pancreatic cancer screening for people with a or mutation. These guidelines recommended:

  • All patients with a mutation regardless of family history of pancreatic cancer, should undergo annual  screening for pancreatic cancer with MRI/MRCP or EUS beginning at age 50 (or 10 years earlier than the earliest pancreatic cancer in the family).  

Updated: 07/03/2022

Expert Guidelines
Expert Guidelines

The National Comprehensive Cancer Network has guidelines on who should undergo genetic counseling and testing. The NCCN recommends genetic counseling and testing for anyone diagnosed with pancreatic cancer, using a comprehensive gene panel for .

Updated: 12/04/2021

Questions To Ask Your Doctor
Questions To Ask Your Doctor

  • Should I have genetic testing for an inherited mutation? 
  • I had genetic testing in the past, should I have additional testing? 
  • Should I have pancreatic cancer screening? 
  • Will my insurance pay for pancreatic cancer screening?

Open Clinical Trials
Open Clinical Trials

Studies enrolling people diagnosed with pancreatic cancer

Studies enrolling people at high risk for pancreatic cancer

Open Clinical Trials
Open Clinical Trials

The following are studies looking at risk management for pancreatic cancer:

A number of other clinical trials for pancreatic cancer screening and prevention may be found here.

Updated: 06/18/2022

Open Clinical Trials
Open Clinical Trials

The following are studies enrolling people diagnosed with pancreatic cancer:

Other clinical trials for people with pancreatic cancer can be found here.

Updated: 08/23/2022

Open Clinical Trials
Open Clinical Trials

The following are studies looking at treatment for people with advanced

Updated: 08/23/2022

Peer Support
Peer Support

The following organizations offer peer support services for people with or at high risk for pancreatic cancer:

Updated: 08/23/2022

Back to XRAY Home